Olaparib demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival, and distant disease-free survival at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. It also reduced the risk of death by 28% in these patients.
Breast Cancers Today
Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.
Advertisement
Latest News
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Researchers aimed to evaluate the roll of ERCC1 expression in predicting response to adjuvant chemotherapy for TNBC.
TILs can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who can reduce adjuvant therapy.
Cancer recurrence fear appreciably impacts breast cancer survivors’ ability to re-enter the workforce.
There was a 29% increase in cancer detection with AI-supported screening.
Researchers found two effective treatments for metaplastic breast cancer.
New research has uncovered a combination therapy that shows promising results in melanoma and breast cancer models.
In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death.
The study used SEER data of nearly 20,000 cases.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.